Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C

(2010) Patrick Marcellin et al.   GASTROENTEROLOGY

Use of HIV Resistance Testing After Prolonged Treatment Interruption

(2010) Dmitri E Iarikov et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

771 DECLINE OF DETECTABLE RESISTANCE MUTATIONS WITHIN THE HCV NS3 PROTEASE QUASISPECIES DURING LONG-TERM FOLLOW-UP AFTER TREATMENT WITH TELAPREVIR

(2010) S. Susser et al.   JOURNAL OF HEPATOLOGY

Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues

(2010) Jurriën G.P. Reijnders et al.   JOURNAL OF HEPATOLOGY

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

(2010) J.M. Vierling et al.   JOURNAL OF HEPATOLOGY

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

(2010) Paul Y Kwo et al.   LANCET

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone

(2009) Ju Hyun Shim et al.   HEPATOLOGY

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

(2009) Simone Susser et al.   HEPATOLOGY

Temporal Dynamics of a Predominant Protease Inhibitor–Resistance Mutation in a Treatment-Naive, Hepatitis C Virus–Infected Individual

(2009) Arthur Y. Kim et al.   JOURNAL OF INFECTIOUS DISEASES

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of HCV protease inhibitor resistance mutations by selection pressure-based method

(2009) P. Qiu et al.   NUCLEIC ACIDS RESEARCH

Characterization of resistance mutations against HCV ketoamide protease inhibitors

(2008) X TONG et al.   ANTIVIRAL RESEARCH

Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient

(2008) Philippe Colson et al.   HEPATOLOGY

Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy

(2008) Silvana Gaudieri et al.   HEPATOLOGY

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

(2008) Thomas Kuntzen et al.   HEPATOLOGY

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

(2008) V. Soriano et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects

(2008) Doug J. Bartels et al.   JOURNAL OF INFECTIOUS DISEASES